Axicabtagene ciloleucel (YESCARTA) is CD19 directed CD28/CD3ζ CAR T-cell therapy which was approved for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma and DLBCL arising from follicular lymphoma in October 2017 [19]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.